Results 51 to 60 of about 5,159 (158)

Evolocumab administration prior to Coronary Artery Bypass Grafting in patients with multivessel coronary artery disease (EVOCABG): study protocol for a randomized controlled clinical trial

Trials, 2022
Background Despite advances in surgical and postoperative care, myocardial injury or infarction (MI) is still a common complication in patients undergoing coronary artery bypass surgery (CABG).
Hye Rim Na, O Sung Kwon, Joon Kyu Kang, Yong Han Kim, Ju Yong Lim   +4 more
doaj   +1 more source

Impact of CYP2C19 Genotype Variants on PCSK9 Inhibitor Efficacy in Lipid‐Lowering Among Patients With Symptomatic Intracranial Atherosclerotic Stenosis

Lipids, Volume 61, Issue 3, Page 319-329, May 2026.
ABSTRACT Ischemic stroke is frequently associated with symptomatic intracranial atherosclerotic stenosis (sICAS), is a leading cause of global disability and mortality. Current guidelines recommend dual antiplatelet and intensive statin therapies. Proprotein convertase subtilisin 9/kexin type 9 (PCSK9) inhibitors have emerged as a potent lipid‐lowering
Chao Zhao, Nuan Wang, Di Shi, Hao Zhou, Dan Chen, Guofang Chen   +5 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Effect of Evolocumab on Coronary Plaque Composition

, 2018
Background: Incremental low-density lipoprotein (LDL) cholesterol lowering with the proprotein convertase subtilisin kexin type 9 inhibitor evolocumab regresses coronary atherosclerosis in statin-treated patients.
Nissen, Steven E., Nicholls, Stephen J., Cho, Leslie, Brennan, Danielle M., Anderson, Todd, Ballantyne, Christie M., Wolski, Kathy, Scherer, Daniel J., Koenig, Wolfgang, Honda, Satoshi, Kassahun, Helina, Puri, Rishi, Yang, Jingyuan, Borgman, Marilyn, Wasserman, Scott M., Shishikura, Daisuke, Somaratne, Ransi, Kastelein, John J. P.   +17 more
core   +1 more source

Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study

Cardiovascular Diabetology, 2023
Background Pericoronary adipose tissue (PCAT) density is a biomarker of vessel inflammation, which is supposed to be increased in patients with type 2 diabetes mellitus (T2DM). However, whether the coronary inflammation revealed by this novel index could
Meng-Meng Yu, Xin Zhao, Yin-Yin Chen, Xin-Wei Tao, Jun-Bo Ge, Hang Jin, Meng-Su Zeng   +6 more
doaj   +1 more source

Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients

Frontiers in Cardiovascular Medicine, 2022
Background and aimsProprotein convertase subtilisin/kexin type 9 (PCSK9) has long been considered a key regulator in lipid metabolism. Its role as a potential player in immune response has recently earned much attention.
Ziwei Ou, Ziwei Ou, Zaixin Yu, Benhui Liang, Lin Zhao, Jianghua Li, Xinli Pang, Qiyun Liu, Cong Xu, Shaohong Dong, Xin Sun, Tangzhiming Li   +11 more
doaj   +1 more source

Extracellular and Membrane Protein: Structure, Biological Functions, Diseases, and an Emerging Modality for Drug Discovery

MedComm, Volume 7, Issue 4, April 2026.
Targeted protein degradation represents a paradigm shift from traditional protein inhibition to complete protein elimination. This is achieved through three main strategies for degrading extracellular and membrane proteins: recruitment of cell‐surface LTRs, engagement of intracellular proteins, and receptor‐independent mechanisms.
Mengqing Zhao, Wenhao Yin, Jianjian Han, Huimin Wang, Zheng Liu, Lilong Liu, Wuxiang Mao   +6 more
wiley   +1 more source

Clinical‐Pharmacological Drug Information Center of Hannover Medical School: Update From a Tertiary Care University Hospital (2022–2024)

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
ABSTRACT Drug information centers (DICs) are institutions dedicated to providing independent and up‐to‐date information on medications and their usage to healthcare professionals. Here, we provide an update from the clinical‐pharmacological DIC of Hannover Medical School, covering the period from April 2022 to December 2024.
Johannes Heck, Dirk O. Stichtenoth, Christoph Schröder, Ruxandra Sabau, Anna‐Leena K. Heim, Felix Koop, Thorben Pape, Sebastian Schröder, Martin Schulze Westhoff, Benjamin Krichevsky, Martin Klietz, Stephan Greten, Carsten Schumacher   +12 more
wiley   +1 more source

Elevated triglyceride‐glucose index is associated with increased risk of chronic kidney disease and end‐stage renal disease in type 1 diabetes: Nationwide cohort study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2784-2794, April 2026.
Abstract Aims Prognostic markers for microvascular complications in type 1 diabetes are needed because factors beyond hyperglycaemia contribute to this risk. The triglyceride‐glucose (TyG) index is an established marker of vascular complications in type 2 diabetes; however, its clinical significance in type 1 diabetes remains unknown.
Rosa Oh, Seohyun Kim, So Hyun Cho, Ji Yoon Kim, Myunghwa Jang, Sang Ho Park, You‐Bin Lee, Sang‐Man Jin, Kyu Yeon Hur, Gyuri Kim, Jae Hyeon Kim   +10 more
wiley   +1 more source

Indirect comparison of the efficacy and safety of alirocumab and evolocumab on major cardiovascular events: a systematic review and network meta-analysis

Frontiers in Pharmacology
BackgroundAlirocumab and evolocumab are proprotein convertase subtilisin/kexin type 9 inhibitors that significantly reduce the relative risk of cardiovascular events.
Leyu Xu, Leyu Xu, Ming Lei, Ming Lei, Liren Li, Liren Li, Yilei Li, Yilei Li, Chunping Gu, Chunping Gu, Ping Zheng, Ping Zheng   +11 more
doaj   +1 more source